VABOREM^®(meropenem/vaborbactam)

VABOREM^®(meropenem/vaborbactam) offers a directed therapy optimised for the treatment of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections.¹

Why are CRE an urgent threat for patients and healthcare systems?

Worldwide, CRE are a major concern for patients in healthcare facilities.² Carbapenem resistance is associated with high healthcare costs, prolonged hospital stays, treatment failure and high mortality rates.^2–4

• The World Health Organization (WHO) has identified extended spectrum beta lactamase (ESBL)-producing, carbapenem-resistant Enterobacterales as critical pathogens of concern⁵
• KPC accounts for 12.5% of carbapenemase-producing Enterobacterales (CPE) reported cases in the UK⁶
• CPE reporting is mandatory, and rapid access to diagnostics for the “big five” carbapenemase families is outlined in the Public Health England (PHE) Toolkit “Framework of actions to contain carbapenemase-producing Enterobacterales”⁷

"Some [Enterobacterales] are resistant to nearly all antibiotics, leaving more toxic or less effective treatment options."²

(Centers for Disease Control and Prevention, USA)

What is VABOREM^®?

VABOREM® is a first-line antibiotic for KPC-CRE infections¹ 

• VABOREM^® is optimised for the treatment of KPC-CRE infections^1,8,9
• A novel cyclic boronate beta-lactamase inhibitor (BLI), vaborbactam has high activity against class A and class C beta-lactamases^1,4,10

Inhibition of beta-lactamases by vaborbactam^8,10,11

Adapted from Hecker et al., 2015,⁸ Dhillon et al., 2018¹⁰ and Toussaint et al., 2014.¹¹

Ambler class	Enzyme	Inhibited by vaborbactam
Class A	Serine carbapenemases (e.g. KPC, NMC-A, SME-2)
	ESBL (e.g. SHV-2, PER-1)
	Narrow spectrum (e.g. TEM-1, TEM-2)
Class B	Metallo-β-lactamase (e.g. VIM-1, NDM-1)
Class C	Cephalopsorinases (e.g. AmpC, P99, ACT-1)
Class D	OXA-48

• Monotherapy with VABOREM^® for CRE infection is associated with increased clinical cure and marked trends towards lower mortality and nephrotoxicity compared with best available therapy (BAT)¹²*

• VABOREM^® has a low incidence of reported on-treatment resistance^13,14

How is Menarini committed to the fight against antimicrobial resistance (AMR)?

Our medical educational programme “Infection in Focus” has been created by Menarini with the purpose of increasing awareness of AMR. We align our activities to best practice as set out in antimicrobial stewardship (AMS) programmes. You can find out more about AMR and AMS here.

Product indications (refer to local SmPC for full details - details may vary between GB and NI):

QUOFENIX^®(delafloxacin) is indicated for the treatment of the following infections in adults: (1) acute bacterial skin and skin structure infections (ABSSSI) (2) community-acquired pneumonia (CAP). Only prescribe when other antibiotics that are commonly recommended for these infections are inappropriate. [Refer to local SmPC for full indication details including risk of prolonged, disabling and potentially irreversible serious adverse drug reactions].¹

VABOREM^®(meropenem/vaborbactam) is indicated for use in adults for the treatment of: complicated urinary tract infection (cUTI) including pyelonephritis; complicated intra-abdominal infection (cIAI); hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP); bacteraemia that occurs in association with, or is suspected to be associated with, any of these previously listed infections; infections due to aerobic Gram-negative organisms in adults with limited treatment options.²⁴

TENKASI^® (oritavancin) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older.

References:

1. VABOREM^® Summary of Product Characteristics.
2. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. December 2019. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html (accessed September 2021).
3. Decraene V et al. Antimicrob Agents Chemother 2018;62(12):e01689–18.
4. Petty LA et al. Infect Drug Resist 2018;11:1461–1472.
5. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. February 2017. Available from: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf (accessed September 2021).
6. Public Health England. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report 2019 to 2020. November 2020. Available from: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report (accessed September 2021).
7. Public Health England. Framework of actions to contain carbapenemase-producing Enterobacterales. Available from: https://www.gov.uk/government/publications/actions-to-contain-carbapenemase-producing-enterobacterales-cpe (accessed September 2021).
8. Hecker SJ et al. J Med Chem 2015;58(9):3682–3692.
9. Bush K, Bradford PA. Nat Rev Microbiol 2019;17(5):295–306.
10. Dhillon S. Drugs 2018;78(12):1259–1270.
11. Toussaint KA et al. Ann Pharmacother 2015;49:86–98.
12. Wunderink RG et al. Infect Dis Ther 2018;7(4): 439–455.
13. Ackley R et al. Antimicrob Agents Chemother 2020; 64: e02313–19.
14. Shields RK et al. Clin Infect Dis 2020; 71: 667–671.
15. Public Health England. Antimicrobial stewardship: Start smart - then focus. March 2015. Available from: https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus (accessed September 2021).
16. QUOFENIX^® Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL. Phone 0800 085 8678 or email: [email protected]

These medicinal products are subject to additional monitoring.